GLP-1 coverage by state · 50 states and DC · state documents checked Oct 17 to Oct 22, 2026
Which States Cover Wegovy and Zepbound in Medicaid? All 50 States and DC
As of October 2026, 10 of 50 states and DC cover GLP-1s for weight loss in Medicaid: 8 at the usual BMI 30 (or 27 with a condition) bar and 2 only at about BMI 40 (Michigan, Virginia). The other 41 do not; 8 of them ended coverage in 2025-2026, and Indiana has announced coverage without a start date. Most still pay for Wegovy for heart risk or MASH and Zepbound for sleep apnea.
- Covers weight loss: 8
- Narrow, BMI 40+: MI, VA (2)
- No weight-loss coverage: 41
- Ended 2025-2026: CA, PA, CT, MA, NH, SC, UT, RI (8)
- Announced, not started: IN (1)
- Medicare Bridge: $50/mo in every state
We may earn a commission when you click links to providers, and partner relationships can affect which providers we feature and their order. Advertiser Disclosure
01 State table
Medicaid GLP-1 Coverage by State: All 50 States and DC
Every row below comes from the state's own drug list, prior authorization (PA) criteria or Medicaid bulletin, read between October 17 and October 22, 2026. "Indication only" means the state pays for Wegovy or Zepbound when the diagnosis is heart disease, MASH (liver disease) or obstructive sleep apnea, never for weight loss alone. In every state, your prescriber files the PA; you cannot file it yourself.
| State | Medicaid weight-loss coverage | Wegovy for heart risk / MASH | Zepbound for sleep apnea | Ozempic / Mounjaro (type 2 diabetes) | 2025-2026 change | State employee plan | Providers serving the state | Guide |
|---|---|---|---|---|---|---|---|---|
| North Carolina | Yes, prior approval: BMI 30+, or 27+ with a weight-related condition; keep 5% off to renew | Covered (stayed covered during the 2025 cut) | Covered, moderate to severe OSA | Ozempic pen and Mounjaro preferred | Cut Oct 1, 2025; reinstated Dec 12, 2025; Zepbound vials removed Sep 4, 2026 | No weight-loss GLP-1s since Apr 1, 2024 (State Health Plan) | 9 | Open guide |
| Tennessee | Yes, PA: BMI above 30, or above 27 with a condition; renew with 5% loss | Heart: PA (BMI 27+) | Not separately listed | Mounjaro, Ozempic preferred with PA | Coverage effective Jan 1, 2026 (Milliman); Wegovy, Zepbound preferred on the Oct 1, 2026 PDL | Not confirmed in a public plan document | 8 | Open guide |
| Missouri | Yes, PA: Zepbound or Foundayo at BMI 30+, or 27+ with a condition | Heart: 45+, BMI 27+, no diabetes. MASH: F2 to F3. Not for weight loss | Preferred for obesity (OSA counts as a condition) | Ozempic and Mounjaro preferred for diabetes | Foundayo added; criteria revised Apr 23, 2026 | Not confirmed in a public plan document | 8 | Open guide |
| Wisconsin | Yes, PA: Zepbound or Foundayo at BMI 30+, or 27 to 30 with 2 risk factors | Adults: heart risk or MASH only | Not separately listed | Covered for type 2 diabetes | Weight management class Jul 1, 2026; Saxenda and older drugs dropped | From Jan 1, 2027: $200 copay | 9 | Open guide |
| Minnesota | Yes, PA: BMI 30+, or 27+ with a condition; renew with 5% loss | Wegovy preferred in Weight Management Agents | Zepbound non-preferred | Ozempic preferred; Mounjaro non-preferred | Incretin class updated Apr 1, 2026 | Not confirmed in a public plan document | 8 | Open guide |
| Kansas | Yes, PA: BMI 30+, or 27+ with a condition; renew with 5% at 12 weeks or 10% at 28 weeks | Wegovy under the general AOM criteria (BMI 40 gate removed Jun 1, 2025) | Zepbound under the general AOM criteria, 28-week first approval | Not checked for this guide | Wegovy freed from the BMI 40 high-cost rule Jun 1, 2025 | Not confirmed in a public plan document | 9 | Open guide |
| Mississippi | Yes, PA: BMI 30+, or 27 to 29 with a condition; renew with 5% loss | Wegovy preferred for weight loss (12+) | Zepbound preferred for weight loss (18+) | Not checked for this guide | Foundayo listed in criteria effective Jul 1, 2026 | Not confirmed in a public plan document | 7 | Open guide |
| Delaware | Yes, PA: BMI 30+, or 27+ with a condition, plus a documented weight-related condition; keep 5% off to renew | Heart: BMI 27 to 29.9 with CVD. MASH: F2 to F3, no BMI rule | On the anti-obesity PA list | Not checked for this guide | State Plan comorbidity rule added Q1 2026; heart and MASH routes added | Not confirmed in a public plan document | 7 | Open guide |
| Michigan | Yes, narrow: BMI 40+, after 5 older drug types fail, only to avert bariatric surgery | Heart: BMI 27+ with established CVD, no BMI 40 rule. MASH: own criteria | Own class and PA criteria | Ozempic pen preferred; Mounjaro moves to preferred Nov 1, 2026 | BMI 40 rule from Jan 1, 2026 (MDHHS letter L 25-73, Dec 8, 2025) | Not confirmed in a public plan document | 9 | Open guide |
| Virginia | Yes, narrow: BMI above 40, or above 37 with a condition, after an older drug fails | Heart and MASH: separate SA forms | Separate SA form | Covered for type 2 diabetes | Weight-loss SA form revised Apr 16, 2026 | COVA Care: Tier 3, $45 a month | 9 | Open guide |
| California | No, ended Jan 1, 2026 (age 21+); under 21 case by case | Heart: PA. MASH: no PA since Apr 1, 2026 with the diagnosis code | PA considered | Covered only with a type 2 diabetes diagnosis on file | Medi-Cal Rx ended weight-loss coverage Jan 1, 2026 | CalPERS HMOs (Blue Shield, Kaiser): BMI 40+ with PA; self-insured PPO: no | 9 | Open guide |
| Texas | No weight-loss route in the PA criteria | Heart: age 45+ with CVD. MASH: F2 to F3 fibrosis, injection only | AHI 15+; 180 days, renew with 5% loss | Ozempic preferred with clinical PA; Mounjaro non-preferred | PA criteria revised May 8, 2026; Wegovy 4 mg tablets added Aug 11, 2026 | ERS HealthSelect: obesity-only drugs excluded; Wegovy for heart risk with PA | 9 | Open guide |
| Florida | No, weight control drugs excluded | No criteria published | No criteria published | Preferred with PA: A1c 6.5%+ and a metformin trial | No change to weight-loss coverage | Weight Management Program 2027: 2,000 places, applications Nov 2 to 6, 2026 | 9 | Open guide |
| New York | No, excluded by regulation | Heart: BMI 40+, 2 attempts per lifetime. MASH: not listed | BMI 40+, 2 attempts per lifetime | Ozempic pen preferred; Mounjaro non-preferred, PA | Criteria in the NYRx list revised Sep 14, 2026 | Empire Plan: Wegovy and Zepbound preferred with PA (Jul 2026) | 10 | Open guide |
| Pennsylvania | No, ended Jan 1, 2026 | Heart (BMI 27+) and MASH, non-preferred, after Ozempic | BMI 35+, last in the PA order | Ozempic pen and tablets preferred; every GLP-1 needs PA; Mounjaro non-preferred | Bulletin Nov 24, 2025; coverage ended Jan 1, 2026; guidelines updated Mar 2, 2026 | PEBTF rules not public | 9 | Open guide |
| Illinois | No, "anorectic drugs" excluded by rule | Wegovy pen and pill: heart risk or MASH, non-preferred | Covered for OSA only, non-preferred | Ozempic tablets preferred with PA; Ozempic pen and Mounjaro after a preferred GLP-1 | Wegovy and Zepbound added for these uses on the Oct 1, 2026 list; Rybelsus to Ozempic tablets (May 21, 2026) | State law requires weight-loss injectables since Jul 1, 2024 | 9 | Open guide |
| Ohio | No, obesity drugs excluded by rule | Heart (BMI 27+) or MASH, PA for 180 days; no Wegovy HD 7.2 mg | Not on the drug list, no published path | Ozempic: PA after 120 days on 3 preferred drugs; Mounjaro: A1C above 7% plus 120 days on Ozempic | Wegovy heart and MASH criteria first listed Apr 1, 2026 | Weight-loss GLP-1s ended Jul 1, 2025; Virta program with partial reimbursement, capped at 2,500 | 9 | Open guide |
| Georgia | No for adults; Saxenda ages 12 to 17 only (with a cholesterol diagnosis) | Not on the drug list | Not on the drug list | Preferred with PA, A1c 6.5%+ (Mounjaro from age 10) | PA rewrite Jul 1, 2026: A1c 7% to 6.5%, step therapy dropped | SHBP covers weight-loss drugs with PA; 9amHealth optional since Oct 1, 2026 | 8 | Open guide |
| New Jersey | No, antiobesics excluded (N.J.A.C. 10:51) | No state criteria published | No state criteria published | Covered for type 2 diabetes | No change found | SHBP: Wegovy, Saxenda, Zepbound $45 per 30 days (2026) | 8 | Open guide |
| Washington | No, "not covered by Apple Health for weight loss" | Heart (BMI 27+) and MASH: PA, no diabetes | PA: BMI above 30, no diabetes | HCA policy 27.17.00 | Wegovy policy updated Feb 1, 2026 | Not confirmed in a public plan document | 9 | Open guide |
| Arizona | No, "medications used for weight loss treatment" excluded | Not confirmed | Not confirmed | Not confirmed (AHCCCS drug list not reachable) | No change found | Not confirmed in a public plan document | 9 | Open guide |
| Massachusetts | No, ended July 2026 | Heart (established CVD) and MASH with a new PA | Moderate to severe OSA with a new PA | Diabetes GLP-1s on the MassHealth Drug List | Obesity coverage ended Jul 1, 2026; older PAs end-dated Jun 30 | Not confirmed in a public plan document | 9 | Open guide |
| Indiana | Not yet: adult coverage announced Jul 30, 2026, start date not set; under 21 case by case | Not confirmed | Not confirmed | Not checked for this guide | BALANCE model joined Jul 30, 2026 (Zepbound, Foundayo) | Not confirmed in a public plan document | 9 | Open guide |
| Maryland | No, weight management excluded (COMAR 10.57.06.27A(12)) | Not confirmed | Not confirmed | Lab-confirmed diabetes required; not for prediabetes | No change found | Not confirmed in a public plan document | 9 | Open guide |
| Colorado | No, PA "solely for weight loss will not be approved" | Heart: BMI 25+ with CVD, no type 2 diabetes. MASH: F2 to F3 | KwikPen preferred; BMI 30+, failed 6-month CPAP trial | Ozempic and Mounjaro preferred for type 2 diabetes | GLP-1 class criteria effective Oct 1, 2026 | Not confirmed in a public plan document | 9 | Open guide |
| South Carolina | No, ended Jan 1, 2026 | No route on the PDL | No route on the PDL | Ozempic, Trulicity preferred; Mounjaro non-preferred | Added Nov 1, 2024; ended Jan 1, 2026 | PEBA: weight-loss medications excluded | 7 | Open guide |
| Alabama | No; Zepbound non-covered for weight reduction without sleep apnea | Wegovy non-preferred, PA (use not stated on the PDL) | Preferred with clinical criteria, OSA with obesity only | Ozempic and Mounjaro preferred with clinical criteria | Mounjaro added as preferred Jan 1, 2026 | Not confirmed in a public plan document | 7 | Open guide |
| Louisiana | No; Zepbound criteria written for sleep apnea only | Not confirmed (LDH criteria not reachable) | AHI 15+ within 12 months, BMI 30+, no diabetes | Not checked for this guide | SB 433 (2026) proposed coverage from Jan 1, 2027 | Not confirmed in a public plan document | 6 | Open guide |
| Kentucky | No, Wegovy for weight loss excluded | Heart: 45+, BMI 27+, on heart drugs, no diabetes. MASH: F2 to F3 | AHI 15+, BMI 30+, 3 months PAP first | Not checked for this guide | Wegovy criteria updated Jan 3, 2026 | Not confirmed in a public plan document | 9 | Open guide |
| Oregon | No, drugs "only for weight management" not covered | Heart and MASH: PA | PA; Zepbound pens preferred | Trulicity, Victoza preferred; Ozempic, Mounjaro non-preferred | Weight Management Drugs criteria implemented Mar 1, 2026 | Not confirmed in a public plan document | 9 | Open guide |
| Oklahoma | No, obesity drugs not covered (OAC 317:30-5-72.1) | Heart (age 45+, A1C under 6.5%) and MASH: PA | PA: AHI 15+ | Covered for type 2 diabetes | 2026 criteria; PA forms revised Sep 2026 | Not confirmed in a public plan document | 8 | Open guide |
| Connecticut | No, ended for weight loss in 2025 (reported; state bulletin not reachable) | Reported: heart and MASH routes (bulletin not reachable) | Reported: OSA route (bulletin not reachable) | Covered for type 2 diabetes | Weight-loss coverage cut in 2025 | Not confirmed in a public plan document | 9 | Open guide |
| Utah | No, pilot ended Jun 30, 2026 | Heart and MASH: PA | PA: 70% CPAP adherence | Per the Medicaid PDL | Weight-loss pilot Jul 1, 2025 to Jun 30, 2026 (fee-for-service) | PEHP: 50% back, up to $150/mo, from Jul 1, 2026 | 8 | Open guide |
| Iowa | No, weight loss excluded (IAC 441-78.2(4)) | Heart: BMI 27+ with CVD, no diabetes. MASH: F2 to F3 | AHI 15+ within 3 years, BMI 30+ | Separate diabetes PA criteria | Non-diabetes PA form revised Jan 2026 | Not confirmed in a public plan document | 8 | Open guide |
| Nevada | No, weight-management agents excluded (MSM 1203) | Heart (cardiologist, no diabetes) and MASH: PA | PA: CPAP compliance, BMI above 30 | Mounjaro and Ozempic tablets preferred with PA from Aug 1, 2026 | Single PDL Jan 1, 2026; Mounjaro preferred Aug 1, 2026 | PEBP: diabetes indication required (May 2026 board) | 9 | Open guide |
| Arkansas | No, "does not cover medications for weight loss" | Heart: BMI 27+ with established CVD. MASH: F2 to F3. Manual PA | AHI 15+, BMI 30+ with a condition, 6 months CPAP first | Non-preferred with PA; Trulicity, Victoza preferred | Wegovy tablets added to heart criteria (memo May 13, 2026) | Not confirmed in a public plan document | 6 | Open guide |
| New Mexico | No, Wegovy, Zepbound, Saxenda listed "not covered" | No state criteria published | No state criteria published | Through Turquoise Care plan formularies | No change found | Not confirmed in a public plan document | 9 | Open guide |
| Idaho | No, per coverage trackers (state PDL not reachable) | Not confirmed | Not confirmed | Covered for type 2 diabetes (trackers) | State employee plan ended weight-loss drugs Nov 1, 2025 | All weight-loss drugs dropped Nov 1, 2025 | 9 | Open guide |
| Nebraska | No, not on the Oct 1, 2026 PDL | No published criteria | No published criteria | Ozempic preferred after metformin; Mounjaro non-preferred | No change found | Not covered, also not for sleep apnea (DAS FAQ) | 9 | Open guide |
| West Virginia | No, weight loss a benefit exclusion | Heart (specialist, A1C 6.5% or less) and MASH: PA | PA since Jul 1, 2025 | Covered for type 2 diabetes | Wegovy criteria effective Jan 1, 2026 | PEIA: diabetes only since Mar 15, 2024 | 7 | Open guide |
| Hawaii | No, "drugs for weight loss... are not covered" (AlohaCare QUEST) | No published criteria found | No published criteria found | Plan formulary, not checked | 2026 bills HB 2456, SB 3195 proposed coverage | Not confirmed in a public plan document | 7 | Open guide |
| New Hampshire | No, ended Jan 1, 2026 | Covered with PA (separate MACE and MASH criteria) | Covered for severe OSA | Type 2 diabetes after an oral drug trial | Weight-loss coverage ended Jan 1, 2026 (notice Oct 9, 2025) | Not confirmed in a public plan document | 9 | Open guide |
| Maine | No, "weight loss drugs are not covered" | Heart or MASH with BMI over 27, not for weight loss only | BMI 30+, AHI 15+ within 3 years, CPAP 90 days first | Rybelsus, Trulicity, Victoza preferred; Ozempic non-preferred | No change found | Not confirmed in a public plan document | 9 | Open guide |
| Montana | No, no weight-loss class on the PDL | Heart (BMI above 27, cardiac specialist) and MASH: PA | PA: AHI 15+, 6 months of CPAP first | Ozempic preferred; Mounjaro non-preferred (2 preferred drugs, 6 months each) | Wegovy PA form updated Aug 2026 | Weight-reduction drugs excluded (2026 plan document) | 9 | Open guide |
| Rhode Island | No, ended Oct 1, 2026 | No route on the PDL | No route on the PDL | Ozempic preferred; Mounjaro non-preferred | Weight management class removed Oct 1, 2026 | Anchor Plan excludes weight-loss drugs | 7 | Open guide |
| South Dakota | No, "No coverage for weight loss" | Wegovy listed for MACE or MASH only | Zepbound listed for OSA only | Listed for type 2 diabetes | No change found | Not confirmed in a public plan document | 8 | Open guide |
| North Dakota | No; obesity covered only with phentermine-type drugs | Semaglutide PA: age 55 to 74, BMI 27 to 34.9; MASH PA | Semaglutide or tirzepatide PA after 6 months of CPAP | Covered for type 2 diabetes; Ozempic also for antipsychotic weight gain | Manual v2026.7, Oct 1, 2026 | NDPERS: no GLP-1 for weight loss | 8 | Open guide |
| Alaska | No, obesity drugs excluded by 7 AAC 120.112 | Wegovy tablets on the PA list since Dec 23, 2025 (2 failed therapies) | No published criteria found | Ozempic no PA; Mounjaro PA after 2 failed therapies | Wegovy tablets added to the PA list Dec 23, 2025 | Not confirmed in a public plan document | 7 | Open guide |
| District of Columbia | No, anti-obesity drugs excluded | No criteria published | No criteria published | On the PDL | No change found | Not confirmed in a public plan document | 4 | Open guide |
| Vermont | No, weight-loss drugs excluded | Wegovy preferred for heart risk or MASH | Zepbound preferred after criteria | Covered for type 2 diabetes after criteria | PDL of Oct 2, 2026 | Not confirmed in a public plan document | 8 | Open guide |
| Wyoming | No, no weight-loss class on the PDL | Wegovy: MASH; heart per separate criteria chart | PA: AHI above 15 | Preferred after a metformin trial | No change found | EGI: covered with a CVS weight program since Jan 1, 2026 | 9 | Open guide |
Sources: each state's PDL, PA criteria and bulletins listed in References; provider counts from each provider's own site (state lists re-read Oct 23, 2026). "Providers serving the state" counts online programs whose own page states they serve that state. Rows for the 20 states added on October 22, 2026 (Alabama to Missouri) were checked that day; where a state document could not be reached, the row and the state guide say so. Rows for Montana to Wyoming and the District of Columbia were checked on October 22, 2026. Every provider count includes Found and MEDvidi only where those programs' own state lists name the state (re-read Oct 23, 2026).
The split is about diagnosis, not drug. Most states that refuse weight-loss coverage still pay for Wegovy to cut heart-event risk or treat MASH, and for Zepbound for obstructive sleep apnea, each with prior authorization. Every state covers GLP-1s for type 2 diabetes, but prescribed only for weight loss they fall under the same exclusions. National background: Medicaid coverage of weight loss shots.
02 Timeline
What Changed in 2025-2026
Between July 2025 and October 2026, eight Medicaid programs ended weight-loss coverage, North Carolina ended and restored it, and Tennessee and Wisconsin added it. Each step is dated from the state's own document where one could be read.
Jul 1, 2025
OH (state employees). The State of Ohio plan stops covering GLP-1s for weight loss; a Virta program with partial reimbursement opens Oct 7, 2025.
Oct 1, 2025
NC. NC Medicaid ends weight-loss coverage, citing state funding shortfalls.
Oct 9, 2025
NH. New Hampshire tells providers weight-loss GLP-1s end on Jan 1, 2026.
Oct 21, 2025
CA. Medi-Cal Rx announces GLP-1s for weight loss will not be a covered benefit.
Nov 24, 2025
PA. DHS bulletin ends obesity coverage for every GLP-1 and moves all GLP-1s into one PA class.
Dec 8, 2025
MI. MDHHS letter L 25-73 sets the BMI 40 rule for obesity GLP-1s.
Dec 12, 2025
NC. Weight-loss coverage reinstated, with the criteria of Sept 30, 2025.
Jan 1, 2026
CA, PA, MI. California and Pennsylvania stop paying for weight-loss GLP-1s; Michigan's BMI 40 rule takes effect. New Hampshire and South Carolina also end weight-loss coverage; TennCare coverage takes effect (Milliman).
Apr 1, 2026
CA, OH. Medi-Cal Rx drops PA for Wegovy for MASH when the diagnosis code is on the claim; Ohio first lists Wegovy for heart risk and MASH.
Jun 30, 2026
UT. Utah's one-year Medicaid weight-loss pilot ends; PEHP opens a GLP-1 reimbursement option for state employees on Jul 1.
Jul 1, 2026
GA, all states. Georgia lowers the Ozempic and Mounjaro A1c bar to 6.5%; the Medicare GLP-1 Bridge starts nationwide. Wisconsin adds Zepbound and Foundayo as preferred weight-loss drugs and drops Saxenda.
Oct 1, 2026
IL, GA. Illinois lists Wegovy (heart, MASH) and Zepbound (sleep apnea); Georgia's state plan makes 9amHealth optional. Rhode Island removes its weight management class.
Nov 1, 2026
MI. Mounjaro becomes preferred for diabetes; Foundayo is added as non-preferred for obesity.
03 Medicare
Medicare Is the Same in Every State
The Medicare GLP-1 Bridge is a federal CMS program, so none of its rules change at a state line. You need Part D (or a Medicare Advantage plan with drug coverage), a qualifying BMI tier and a prior authorization from your prescriber.
BMI tiers (BMI at the start of GLP-1 therapy): 35 or higher; 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension or chronic kidney disease stage 3a or higher; 27 or higher with prediabetes, a prior heart attack, a prior stroke or symptomatic peripheral artery disease. Most Medicaid programs in the table set a higher bar for weight loss, or none at all, so people with both Medicare and Medicaid should ask which benefit pays first. Steps: Medicare GLP-1 Bridge.
Free Medicare counseling in each state (SHIP), with the state program's own name and phone line from the national SHIP directory (shiphelp.org, read Oct 22 and 23, 2026):
| State | SHIP program |
|---|---|
| Alabama | Senior Health Insurance Program (SHIP), 800-243-5463 |
| Alaska | Senior Health Insurance Program (SHIP), 800-478-6065 |
| Arizona | Arizona State Health Insurance Assistance Program (SHIP), 800-432-4040 |
| Arkansas | Senior Health Insurance Information Program (SHIIP), 800-224-6330 |
| California | California Health Insurance Counseling and Advocacy Program (HICAP), 800-434-0222 |
| Colorado | State Health Insurance Assistance Program (SHIP), 888-696-7213 |
| Connecticut | Connecticut's Program for Health Insurance Assistance, Outreach, Information and Referral, Counseling, Eligibility Screening (CHOICES), 800-994-9422 |
| Delaware | Delaware Medicare Assistance Bureau, 800-336-9500 |
| District of Columbia | DC State Health Insurance Assistance Program (SHIP), 202-727-8370 |
| Florida | Serving Health Insurance Needs of Elders (SHINE), 800-963-5337 |
| Georgia | Georgia State Health Insurance Assistance Program (GeorgiaCares), 866-552-4464, option 4 |
| Hawaii | Hawaii State Health Insurance Assistance Program (SHIP), 888-875-9229 |
| Idaho | Senior Health Insurance Benefits Advisors (SHIBA), 800-247-4422 |
| Illinois | Senior Health Insurance Program (SHIP), 800-252-8966 |
| Indiana | State Health Insurance Assistance Program (SHIP), 800-452-4800 |
| Iowa | Senior Health Insurance Information Program (SHIIP), 800-351-4664 |
| Kansas | Senior Health Insurance Counseling for Kansas (SHICK), 800-860-5260 |
| Kentucky | State Health Insurance Assistance Program (SHIP), 877-293-7447 |
| Louisiana | Senior Health Insurance Information Program (SHIIP), 800-259-5300 |
| Maine | Maine State Health Insurance Assistance Program (SHIP), 800-262-2232 |
| Maryland | State Health Insurance Assistance Program (SHIP), 800-243-3425 |
| Massachusetts | Serving Health Insurance Needs of Everyone (SHINE), 800-243-4636 |
| Michigan | Michigan State Health Insurance Assistance Program (SHIP), 800-803-7174 |
| Minnesota | Minnesota Aging Pathways, 800-333-2433 |
| Mississippi | State Health Insurance Assistance Program (SHIP), 844-822-4622 |
| Missouri | Missouri State Health Insurance Assistance Program (SHIP), 800-390-3330 |
| Montana | Montana State Health Insurance Assistance Program (SHIP), 406-444-4077 |
| Nebraska | Nebraska SHIP, 800-234-7119 |
| Nevada | Nevada Medicare Assistance Program (MAP), 800-307-4444 |
| New Hampshire | New Hampshire State Health Insurance Assistance Program (SHIP) ServiceLink Resource Center, 866-634-9412 |
| New Jersey | State Health Insurance Assistance Program (SHIP), 800-792-8820 |
| New Mexico | New Mexico ADRC State Health Insurance Assistance Program (SHIP), 800-432-2080 |
| New York | Health Insurance Information, Counseling and Assistance (HIICAP), 800-701-0501 |
| North Carolina | Seniors' Health Insurance Information Program (SHIIP), 855-408-1212 |
| North Dakota | State Health Insurance Counseling Program (SHIC), 888-575-6611 |
| Ohio | Ohio Senior Health Insurance Information Program (OSHIIP), 800-686-1578 |
| Oklahoma | Senior Health Insurance Counseling Program (SHIP), 800-763-2828 |
| Oregon | Senior Health Insurance Benefits Assistance (SHIBA), 800-722-4134 |
| Pennsylvania | PA MEDI (Pennsylvania Medicare Education and Decision Insight), 800-783-7067 |
| Rhode Island | Senior Health Insurance Program (SHIP), 888-884-8721 |
| South Carolina | State Health Insurance Assistance Program (SHIP), 800-868-9095 |
| South Dakota | Senior Health Information and Insurance Education (SHIINE), 888-854-5321 |
| Tennessee | State Health Insurance Assistance Program (SHIP), 877-801-0044 |
| Texas | Health Information, Counseling, and Advocacy Program (HICAP), 800-252-9240 |
| Utah | Senior Health Insurance Information Program (SHIP), 800-541-7735 |
| Vermont | State Health Insurance Assistance Program (SHIP), 800-642-5119 |
| Virginia | Virginia Insurance Counseling & Assistance Program (VICAP), 800-552-3402 |
| Washington | Statewide Health Insurance Benefits Advisors (SHIBA), 800-562-6900 |
| West Virginia | State Health Insurance Assistance Program (SHIP), 877-987-4463 |
| Wisconsin | State Health Insurance Assistance Program (SHIP), 800-242-1060 |
| Wyoming | State Health Insurance Assistance Program (SHIP), 800-856-4398 |
04 Self-pay
Self-Pay Prices Are National
No state sets its own GLP-1 price, so a Medicaid denial anywhere leads to the same manufacturer self-pay prices, as of October 2026.
| Drug | Self-pay per month | Channel |
|---|---|---|
| Wegovy pill | $149 (1.5 mg), $199 (4 mg), $299 (9 and 25 mg) | NovoCare |
| Wegovy pen | $199 for the first 2 fills (new patients, through Dec 31, 2026), then $349; Wegovy HD $399 | NovoCare |
| Zepbound vial or KwikPen | $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg) with a refill within 45 days | LillyDirect |
| Foundayo | from $149 (0.8 mg) | LillyDirect |
Medicaid cannot be billed for these, and manufacturer $25 savings cards exclude government insurance. Every channel, including TrumpRx and Costco: GLP-1 cost.
05 Next steps
If Medicaid Says No
- 1Check for a covered diagnosis. In most states without weight-loss coverage, Wegovy or Zepbound is still covered for heart disease, MASH or sleep apnea. Ask your prescriber whether one applies; never ask for a diagnosis you do not have.
- 2Send the records with the PA. States ask for earlier treatments with dates and results, labs and test results (a sleep study for sleep apnea, a fibrosis test for MASH). Some claims also need the diagnosis code on the prescription, as with Wegovy for MASH in California. Our BMI calculator gives the number most forms ask for.
- 3Ask for the denial reason in writing. Call your state's Medicaid member line or your managed care plan, and ask about an appeal or a State Fair Hearing if the denial stands. Each state guide lists the line.
- 4Under 21? Ask about EPSDT. California reviews weight-loss PA requests for members under 21 one by one under the federal EPSDT benefit, Oregon does the same, and one Pennsylvania plan says so too. Ask your plan in writing.
- 5Check Medicare and cash routes. If you also have Medicare, the $50 Bridge has a lower BMI bar than most Medicaid programs here. Otherwise, the lowest self-pay starting prices are the Wegovy pill and Foundayo, both from $149 a month.
Need a prescriber for steps 1 to 3? The hero visit link (PlushCare) covers it; check whether PlushCare accepts your coverage before booking.
06 FAQ
Medicaid GLP-1 Coverage by State: FAQ
Which states cover Wegovy in Medicaid for weight loss?
Which states cover Wegovy or Zepbound in Medicaid only for other conditions?
Which states stopped Medicaid coverage of GLP-1s for weight loss?
Does Medicaid cover Ozempic and Mounjaro in every state?
Is Medicare GLP-1 coverage different by state?
07 By insurer
Not on Medicaid? Coverage by Insurer
Employer and Medicare plans follow the insurer's rules, not the state's Medicaid program. What each publishes, with dates: Medicare, Blue Cross Blue Shield, UnitedHealthcare, Aetna, Cigna and Kaiser Permanente. All payer types side by side: GLP-1 cost with insurance.
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or qualified health provider with any questions about a medical condition or medication. Never disregard professional medical advice or delay seeking it because of something you have read on this website.
References
- Important Update: GLP-1s for Weight Loss Are Not a Covered Benefit, checked 2026-10-17; document dated Oct 21, 2025, DHCS Medi-Cal Rx
- GLP-1 Coverage Considerations, checked 2026-10-17; document dated Dec 12, 2025, updated Apr 6, 2026, DHCS Medi-Cal Rx
- Changes to GLP-1 Drug Coverage for Wegovy, checked 2026-10-17; document dated Apr 6, 2026, DHCS Medi-Cal Rx
- Agenda Item 8c, Senate Bill 1089 (Richardson), checked 2026-10-17; document dated Jun 17, 2026, CalPERS Board of Administration
- Clinical Criteria: Wegovy (Semaglutide), checked 2026-10-17; document dated Revised May 8, 2026, Texas Prior Authorization Program (Acentra Health for HHSC)
- Clinical Criteria: Zepbound (Tirzepatide), checked 2026-10-17; document dated Revised May 8, 2026, Texas Prior Authorization Program
- Clinical Criteria: GLP-1 Receptor Agonists, checked 2026-10-17; document dated Apr 3, 2026, Texas Prior Authorization Program
- Texas Medicaid Preferred Drug List, checked 2026-10-17; document dated Effective Jul 24, 2026, Texas HHSC
- HealthSelect of Texas Prescription Drug Program, Master Benefit Plan Document, checked 2026-10-17; document dated Effective Sep 1, 2024, ERS / Express Scripts
- Florida Medicaid Preferred Drug List, checked 2026-10-17; document dated Effective Oct 1, 2026, AHCA
- Prior Authorization Criteria: GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists, checked 2026-10-17; document dated Revised Jul 2, 2026, AHCA Pharmacy Policy
- Florida Medicaid Prescribed Drug Services Coverage Policy (Rule 59G-4.250, F.A.C.), checked 2026-10-17; document dated December 2017, AHCA
- Weight Management Program, checked 2026-10-17, Florida Department of Management Services, Division of State Group Insurance
- NYRx Preferred Drug List, checked 2026-10-17; document dated Revised Sep 14, 2026, NYRx, the Medicaid Drug Program (NYS DOH)
- 18 NYCRR 505.3(g), Limitations, checked 2026-10-17, New York Codes, Rules and Regulations
- 2026 Empire Plan Advanced Flexible Formulary Preferred Drug List, checked 2026-10-17; document dated July 2026, NY Department of Civil Service, NYSHIP
- Coverage Change and Prior Authorization of Obesity Treatment Agents, checked 2026-10-17; document dated Nov 24, 2025, effective Jan 1, 2026, PA DHS Medical Assistance Bulletin
- Prior Authorization of GLP-1 Receptor Agonists, checked 2026-10-17; document dated Mar 2, 2026, PA DHS Medical Assistance Bulletin
- Statewide Preferred Drug List, v16, checked 2026-10-17; document dated Effective January 2026, PA DHS
- GLP-1 Drugs to Treat Overweight and Obesity, Doc. No. 25-1777, checked 2026-10-17; document dated Dec 27, 2025, Pennsylvania Bulletin
- Illinois Medicaid Preferred Drug List, checked 2026-10-17; document dated Effective Oct 1, 2026, Illinois HFS
- Provider Notice (Rybelsus to Ozempic tablets), checked 2026-10-17; document dated May 21, 2026, Illinois HFS
- 89 Ill. Adm. Code 140.441, Pharmacy Services Not Covered, checked 2026-10-17, Illinois HFS rule
- State Employees Group Insurance Program Benefits Handbook (5 ILCS 375/6.11c), checked 2026-10-17; document dated Revised Oct 2025, Illinois CMS
- Unified Preferred Drug List, checked 2026-10-17; document dated Effective Oct 1, 2026, Ohio Department of Medicaid
- Unified Preferred Drug List, checked 2026-10-17; document dated Effective Apr 1, 2026, Ohio Department of Medicaid
- Ohio Admin. Code 5160-9-03, Pharmacy services: covered drugs and associated limitations, checked 2026-10-17; document dated Effective Feb 16, 2024, Ohio Department of Medicaid
- State of Ohio benefits package update (GLP-1 weight loss coverage ends Jul 1, 2025), checked 2026-10-17, Ohio DAS
- New weight loss benefit coming Oct. 7, checked 2026-10-17; document dated Sep 30, 2025, Ohio DAS
- Georgia Medicaid/PeachCare Preferred Drug List by drug class, checked 2026-10-17; document dated Effective Sep 1, 2026, Georgia DCH
- Antidiabetic Agents PA Summary, checked 2026-10-17; document dated Revised Jul 1, 2026, Georgia DCH
- Antihyperlipidemics, Other PA Summary (Xenical, Saxenda), checked 2026-10-17, Georgia DCH
- 9amHealth Weight Management Program, checked 2026-10-17, Georgia State Health Benefit Plan
- NC Medicaid to Change Coverage of GLP-1 Weight Management Medications, checked 2026-10-17; document dated Sep 5, 2025, NC Medicaid (NCDHHS)
- NC Medicaid to Reinstitute Coverage of GLP-1s for Weight Management, checked 2026-10-17; document dated Dec 19, 2025, NC Medicaid
- NC Medicaid Preferred Drug List, checked 2026-10-17; document dated Effective October 2026 (revised Sep 21, 2026), NC Medicaid
- Outpatient Pharmacy Prior Approval Criteria, GLP-1s for Weight Management, checked 2026-10-17; document dated Effective Aug 1, 2024, NC Medicaid
- Statement Regarding GLP-1 Coverage, checked 2026-10-17; document dated Mar 7, 2024, NC State Health Plan
- Numbered Letter L 25-73, Update of Pharmacy Drug Coverage for Treatment of Obesity, checked 2026-10-17; document dated Dec 8, 2025, MDHHS
- Michigan Preferred Drug List / Single PDL, checked 2026-10-17; document dated Effective Oct 1, 2026, MDHHS (Prime Therapeutics)
- Michigan Preferred Drug List changes, checked 2026-10-17; document dated Changes effective Nov 1, 2026, MDHHS (Prime Therapeutics)
- Michigan Medicaid Clinical and PDL Criteria, checked 2026-10-17; document dated Sep 2026, MDHHS (Prime Therapeutics)
- Medicare GLP-1 Bridge: information for Part D plans, checked 2026-10-17, CMS
- Weight Management Drugs PA criteria (implemented Mar 1, 2026), checked 2026-10-22, Oregon Health Authority
- TennCare Clinical Criteria, Oct 1, 2026, checked 2026-10-22, TennCare / OptumRx
- ForwardHealth Update 2026-15 (July 2026 PDL changes), checked 2026-10-22, Wisconsin DHS
- Service Authorization Form: Weight-Loss Management, rev. Apr 16, 2026, checked 2026-10-22, Virginia DMAS
- Change in Medicaid Coverage for GLP-1 Medications (Oct 9, 2025), checked 2026-10-22, NH DHHS
- Single Preferred Drug List, Oct 1, 2026, checked 2026-10-22, South Carolina DHHS
- PA form: GLP-1 Medications for Weight-related Comorbidities, Jun 1, 2026, checked 2026-10-22, Utah Medicaid
- Medicaid FFS Preferred Drug List, Oct 1, 2026, checked 2026-10-22, Rhode Island EOHHS
- Medicaid Services Manual Chapter 1200 (posted Oct 5, 2026), checked 2026-10-22, Nevada Health Authority
- Medical policy 61.25.20.AA-4: Wegovy, Feb 1, 2026, checked 2026-10-22, Washington HCA
- State Health Insurance Assistance Program directory, checked 2026-10-22 and 2026-10-23, SHIP Technical Assistance Center (shiphelp.org)